vs

Side-by-side financial comparison of STANDARD BIOTOOLS INC. (LAB) and RAPID MICRO BIOSYSTEMS, INC. (RPID). Click either name above to swap in a different company.

RAPID MICRO BIOSYSTEMS, INC. is the larger business by last-quarter revenue ($11.3M vs $3.2M, roughly 3.5× STANDARD BIOTOOLS INC.). STANDARD BIOTOOLS INC. runs the higher net margin — 598.5% vs -110.8%, a 709.2% gap on every dollar of revenue. On growth, STANDARD BIOTOOLS INC. posted the faster year-over-year revenue change (262.0% vs 37.3%). STANDARD BIOTOOLS INC. produced more free cash flow last quarter ($-1.7M vs $-3.3M). Over the past eight quarters, RAPID MICRO BIOSYSTEMS, INC.'s revenue compounded faster (41.8% CAGR vs -73.4%).

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

Rapid Micro Biosystems, Inc. develops and manufactures automated microbial detection and quality control solutions for the life sciences industry. Its core products serve biopharmaceutical manufacturers, contract development and manufacturing organizations, operating across key global markets including North America, Europe and Asia-Pacific, helping clients cut testing timelines and improve operational efficiency.

LAB vs RPID — Head-to-Head

Bigger by revenue
RPID
RPID
3.5× larger
RPID
$11.3M
$3.2M
LAB
Growing faster (revenue YoY)
LAB
LAB
+224.7% gap
LAB
262.0%
37.3%
RPID
Higher net margin
LAB
LAB
709.2% more per $
LAB
598.5%
-110.8%
RPID
More free cash flow
LAB
LAB
$1.7M more FCF
LAB
$-1.7M
$-3.3M
RPID
Faster 2-yr revenue CAGR
RPID
RPID
Annualised
RPID
41.8%
-73.4%
LAB

Income Statement — Q4 2025 vs Q4 2025

Metric
LAB
LAB
RPID
RPID
Revenue
$3.2M
$11.3M
Net Profit
$19.3M
$-12.5M
Gross Margin
83.5%
Operating Margin
-578.6%
-108.2%
Net Margin
598.5%
-110.8%
Revenue YoY
262.0%
37.3%
Net Profit YoY
156.6%
-29.3%
EPS (diluted)
$0.05
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
LAB
LAB
RPID
RPID
Q4 25
$3.2M
$11.3M
Q3 25
$19.6M
$7.8M
Q2 25
$21.8M
$7.3M
Q1 25
$40.8M
$7.2M
Q4 24
$890.0K
$8.2M
Q3 24
$22.1M
$7.6M
Q2 24
$22.5M
$6.6M
Q1 24
$45.5M
$5.6M
Net Profit
LAB
LAB
RPID
RPID
Q4 25
$19.3M
$-12.5M
Q3 25
$-34.7M
$-11.5M
Q2 25
$-33.5M
$-11.9M
Q1 25
$-26.0M
$-11.3M
Q4 24
$-34.1M
$-9.7M
Q3 24
$-26.9M
$-11.3M
Q2 24
$-45.7M
$-12.6M
Q1 24
$-32.2M
$-13.3M
Gross Margin
LAB
LAB
RPID
RPID
Q4 25
83.5%
Q3 25
48.5%
Q2 25
48.8%
Q1 25
48.4%
Q4 24
-202.8%
Q3 24
54.9%
Q2 24
46.1%
Q1 24
53.1%
Operating Margin
LAB
LAB
RPID
RPID
Q4 25
-578.6%
-108.2%
Q3 25
-168.5%
-145.1%
Q2 25
-118.1%
-167.3%
Q1 25
-80.8%
-161.8%
Q4 24
-1162.1%
-124.5%
Q3 24
-120.9%
-158.3%
Q2 24
-134.5%
-202.1%
Q1 24
-132.2%
-254.4%
Net Margin
LAB
LAB
RPID
RPID
Q4 25
598.5%
-110.8%
Q3 25
-177.4%
-146.8%
Q2 25
-153.7%
-163.3%
Q1 25
-63.8%
-156.3%
Q4 24
-3828.3%
-117.6%
Q3 24
-122.0%
-148.9%
Q2 24
-203.3%
-190.1%
Q1 24
-70.6%
-237.4%
EPS (diluted)
LAB
LAB
RPID
RPID
Q4 25
$0.05
$-0.26
Q3 25
$-0.09
$-0.26
Q2 25
$-0.09
$-0.27
Q1 25
$-0.07
$-0.26
Q4 24
$-0.06
$-0.22
Q3 24
$-0.07
$-0.26
Q2 24
$-0.12
$-0.29
Q1 24
$-0.27
$-0.31

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
LAB
LAB
RPID
RPID
Cash + ST InvestmentsLiquidity on hand
$120.9M
$20.0M
Total DebtLower is stronger
Stockholders' EquityBook value
$424.3M
$33.2M
Total Assets
$567.8M
$74.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
LAB
LAB
RPID
RPID
Q4 25
$120.9M
$20.0M
Q3 25
$129.4M
$18.9M
Q2 25
$158.6M
$18.3M
Q1 25
$150.9M
$18.9M
Q4 24
$166.7M
$16.9M
Q3 24
$210.6M
$22.0M
Q2 24
$269.8M
$37.1M
Q1 24
$287.1M
$22.4M
Total Debt
LAB
LAB
RPID
RPID
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$299.0K
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
LAB
LAB
RPID
RPID
Q4 25
$424.3M
$33.2M
Q3 25
$399.7M
$44.3M
Q2 25
$424.5M
$54.5M
Q1 25
$454.6M
$65.5M
Q4 24
$471.7M
$75.4M
Q3 24
$489.3M
$84.4M
Q2 24
$510.3M
$94.6M
Q1 24
$577.3M
$105.9M
Total Assets
LAB
LAB
RPID
RPID
Q4 25
$567.8M
$74.9M
Q3 25
$539.6M
$84.4M
Q2 25
$557.0M
$75.6M
Q1 25
$579.6M
$85.4M
Q4 24
$612.3M
$98.2M
Q3 24
$681.5M
$105.8M
Q2 24
$708.7M
$117.1M
Q1 24
$777.7M
$127.7M
Debt / Equity
LAB
LAB
RPID
RPID
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
LAB
LAB
RPID
RPID
Operating Cash FlowLast quarter
$-1.2M
$-3.2M
Free Cash FlowOCF − Capex
$-1.7M
$-3.3M
FCF MarginFCF / Revenue
-51.7%
-29.6%
Capex IntensityCapex / Revenue
14.8%
0.8%
Cash ConversionOCF / Net Profit
-0.06×
TTM Free Cash FlowTrailing 4 quarters
$-82.6M
$-31.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
LAB
LAB
RPID
RPID
Q4 25
$-1.2M
$-3.2M
Q3 25
$-22.2M
$-9.1M
Q2 25
$-20.7M
$-9.7M
Q1 25
$-30.3M
$-9.1M
Q4 24
$-14.1M
$-9.9M
Q3 24
$-27.9M
$-8.6M
Q2 24
$-39.0M
$-10.1M
Q1 24
$-62.5M
$-15.5M
Free Cash Flow
LAB
LAB
RPID
RPID
Q4 25
$-1.7M
$-3.3M
Q3 25
$-23.1M
$-9.1M
Q2 25
$-22.6M
$-10.1M
Q1 25
$-35.3M
$-9.4M
Q4 24
$-17.4M
$-10.0M
Q3 24
$-30.1M
$-8.8M
Q2 24
$-41.0M
$-10.6M
Q1 24
$-63.3M
$-16.1M
FCF Margin
LAB
LAB
RPID
RPID
Q4 25
-51.7%
-29.6%
Q3 25
-118.1%
-116.4%
Q2 25
-103.6%
-138.6%
Q1 25
-86.6%
-130.2%
Q4 24
-1959.7%
-121.8%
Q3 24
-136.4%
-116.0%
Q2 24
-182.2%
-159.8%
Q1 24
-138.9%
-287.1%
Capex Intensity
LAB
LAB
RPID
RPID
Q4 25
14.8%
0.8%
Q3 25
4.5%
0.9%
Q2 25
8.7%
5.0%
Q1 25
12.4%
4.4%
Q4 24
380.0%
1.2%
Q3 24
10.2%
2.9%
Q2 24
8.6%
6.9%
Q1 24
1.7%
10.4%
Cash Conversion
LAB
LAB
RPID
RPID
Q4 25
-0.06×
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

LAB
LAB

Segment breakdown not available.

RPID
RPID

Products$9.3M83%
Services$2.0M17%

Related Comparisons